Welcome to our dedicated page for Zenas BioPharma SEC filings (Ticker: ZBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Zenas BioPharma, Inc. (ZBIO) has filed an automatic shelf registration statement on Form S-3 to register the resale of up to 7,000,000 already-issued shares of common stock held by InnoCare Pharma Inc. The company is not offering any shares and will not receive proceeds from these sales; all proceeds go to the selling stockholder, while Zenas bears the registration costs.
The shares were issued to InnoCare under a broader strategic relationship, including an October 2025 license agreement for orelabrutinib and early-stage candidates ZB021 and ZB022, and related subscription and registration rights agreements. Zenas paid $35.0 million in upfront cash and issued 5,000,000 shares initially, then upon an August 2026 regulatory milestone became obligated to pay an additional $25.0 million and issue 2,000,000 more shares. InnoCare’s transfers are contractually volume-limited after an initial lock-up ending October 7, 2026.
Zenas highlights its immunology and inflammation pipeline led by obexelimab, which met the primary and key secondary endpoints in a Phase 3 IgG4‑RD trial and has a BLA accepted by the FDA with a PDUFA target date of May 27, 2027. The filing confirms Zenas’ status as a well-known seasoned issuer and outlines extensive forward‑looking risks tied to clinical progress, regulatory outcomes, financing needs and market conditions.
For Zenas BioPharma, Inc. (ZBIO), a group of Wellington investment entities filed a Schedule 13G reporting passive beneficial ownership of Zenas common stock. They report aggregate beneficial ownership of 6,566,134 shares of common stock, representing 10.07% of the outstanding class.
The Wellington entities report no sole voting or dispositive power, but shared voting power over 6,308,474 shares and shared dispositive power over 6,566,134 shares, held in client accounts advised by various Wellington investment advisers. The filing notes that clients, including Vanguard Health Care Fund, have rights to dividends or sale proceeds, but no individual client is known to hold more than five percent of the class.
Zenas BioPharma, Inc. (ZBIO) reports that InnoCare Pharma Inc. has filed an initial statement of beneficial ownership as a ten percent owner. The filing lists 7,000,000 shares of Common Stock held directly as of August 26, 2026, with no specific acquisition or disposal transaction reported.
Zenas BioPharma, Inc. (ZBIO) received an amended Schedule 13G/A filing in which InnoCare Pharma Inc., Ocean Prominent Limited and InnoCare Pharma Limited report a passive ownership stake. The reporting group states beneficial ownership of 7,000,000 shares of Zenas BioPharma common stock held directly by InnoCare Pharma Inc., a wholly owned subsidiary of Ocean Prominent Limited, which is wholly owned by InnoCare Pharma Limited.
The stake represents 10.4% of Zenas BioPharma’s common stock, calculated from 65,176,723 shares outstanding as of July 31, 2026 plus 2,000,000 shares issued to InnoCare Pharma Inc. in a milestone-triggered private placement that closed on August 31, 2026. The reporting persons indicate shared voting and dispositive power over the 7,000,000 shares and disclaim status as a group for this amendment.
Zenas BioPharma, Inc. (ZBIO) reported that director Christy J. Oliger received a grant of 37,000 stock options on September 1, 2026. The options have an exercise price of $31.98 per share and expire on August 31, 2036. The award vests in equal annual installments over three years beginning September 1, 2027, subject to continued service, and no Rule 10b5-1 trading plan is reported.
Zenas BioPharma, Inc. (ZBIO) reports that Christy J. Oliger has filed an initial statement of beneficial ownership on Form 3 in the capacity of director. The filing lists no equity holdings or reportable transactions and notes an Exhibit 24 Power of Attorney authorizing filing actions.
Zenas BioPharma, Inc. (ZBIO) received an amended Schedule 13D/A from Enavate Sciences GP, LLC and Zebra Aggregator entities updating their ownership in the company’s common stock. The filing reports that Zebra LP directly holds 3,245,404 shares of Zenas common stock, over which Enavate GP shares voting and investment authority.
Based on 65,176,723 Zenas shares outstanding as of July 31, 2026, the reporting group beneficially owns 4.98% of the company’s common stock, which EDGAR displays as 4.9% due to rounding. On August 19, 2026, Zebra LP executed an open market sale of 673,755 shares at a weighted average price of $31.44 per share, within a range of $31.05–$32.00. As a result, the reporting persons state that they ceased to be beneficial owners of more than five percent of Zenas’ common stock on August 19, 2026.
Zenas BioPharma, Inc. (ZBIO) received a Rule 144 notice indicating that Zebra Aggregator, an affiliate, plans to sell up to 1,000,000 shares of Zenas common stock through J.P. Morgan Securities LLC. The filing lists an aggregate market value for the proposed sale of $31,910,000 and states that Zenas had 65,176,723 shares outstanding. The notice identifies a listed sale date of August 19, 2026. The common shares to be sold were acquired from the issuer for cash on November 1, 2022 in connection with a Series B transaction.
An amendment to Schedule 13D reports the current ownership of Zenas BioPharma, Inc. common stock by SR One-affiliated investment vehicles and Simeon George, M.D. Together, the reporting persons beneficially own 5,037,854 shares, representing 7.7% of Zenas’ 65,176,723 outstanding shares as of July 31, 2026. All voting and dispositive authority is reported as shared rather than sole. The change triggering this amendment reflects a decrease of more than 1 percentage point in beneficial ownership percentage due to an increase in Zenas’ shares outstanding, not because of recent share transactions, as no trades in the last 60 days are reported.
Zenas BioPharma, Inc. reported second-quarter 2026 results as a clinical-stage immunology company with no product sales and modest $1.0 million of license and collaboration revenue for both the quarter and first half, compared with $10.0 million in the prior-year six-month period.
Spending accelerated significantly as programs advanced. Research and development expenses reached $62.9 million in the quarter and $123.4 million year-to-date, including $61.2 million tied to lead asset obexelimab and $21.3 million for newly licensed orelabrutinib. The company also recorded $30.0 million of acquired in‑process R&D milestones related to Xencor and InnoCare agreements. General and administrative costs were $15.7 million in the quarter.
These investments drove a quarterly net loss of $111.5 million and a first-half net loss of $192.4 million, more than double the prior-year period, while the accumulated deficit rose to $957.6 million. To support its pipeline, Zenas strengthened its balance sheet, ending June 30, 2026 with $673.9 million in cash, cash equivalents and investments and stating this is sufficient to fund operations for at least twelve months. The company added leverage via a $75.0 million senior secured term loan, $230.0 million of 2.50% convertible senior notes due 2032, and recognized a $91.7 million royalty obligation liability from a Royalty Pharma financing.